Synthesis and Regioselective Reaction of Some Unsymmetrical Heterocyclic Chalcone Derivatives and Spiro Heterocyclic Compounds as Antibacterial Agents

Maher A. El-Hashash, Sameh A. Rizk * and Saad R. Atta-Allah

Received: 19 October 2015 ; Accepted: 3 December 2015 ; Published: 10 December 2015
Academic Editor: Philippe Belmont

Chemistry Department, Science Faculty, Ain-Shams University, Abassia, Cairo 11566, Egypt; maeelhashash@yahoo.com (M.A.E.-H.); saaddr1964@yahoo.com (S.R.A.-A.)
* Correspondence: samehrizk@sci.asu.edu.eg or samehrizk2006@gmail.com; Tel.: +20-106-482-7759

Abstract: A number of novel heterocyclic chalcone derivatives can be synthesized by thermal and microwave tools. Treatment of 4-(4-Acetylamino- and/or 4-bromo-phenyl)-4-oxobut-2-enoic acids with hydrogen peroxide in alkaline medium were afforded oxirane derivatives 2. Reaction of the epoxide 2 with 2-amino-5-aryl-1,3,4-thiadiazole derivatives yielded chalcone of imidazo[2,1-b]thiadiazole derivative 4 via two thermal routes. In one pot reaction of 4-bromoacetophenone, diethyloxalate, and 2-amino-5-aryl-1,3,4-thiadiazole derivatives in MW irradiation (W 250 and T 150 °C) under eco-friendly conditions afforded an unsuitable yield of the desired chalcone 4d. The chalcone derivatives 4 were used as a key starting material to synthesize some new spiroheterocyclic compounds via Michael and aza-Michael adducts. The chalcone 4f was similar to the aryl-oxo-vinylamide derivatives for the inhibition of tyrosine kinase and cancer cell growth. The electron-withdrawing substituents, such as halogens, and 2-amino-1,3,4-thiadiazole moiety decreasing the electron density, thereby decreasing the energy of HOMO, and the presence of imidazothiadiazole moiety should improve the antibacterial activity. Thus, the newly synthesized compounds were evaluated for their anti-bacterial activity against (ATCC 25923), (ATCC 10987), (ATCC 274), and (SM514). The structure of the newly synthesized compounds was confirmed by elemental analysis and spectroscopic data.

Keywords: 4-aryl-4-oxo-but-2-enoic acid; oxirane; chalcone; imidazo[2,1-b]thiadiazole; spiropyrazole; spiroisoxazole; spiropyrene

1. Introduction

The anti-proliferative activity of (E)-4-aryl-4-oxo-2-butenoic acid amides was shown against three human tumor cell lines [1], in addition to a multitude of biological activities [2]. Chalcone derivatives are one of the major classes of natural products with widespread distribution in fruits, vegetables, spices, tea and soy based foodstuff. Recently, they have been a subject of great interest for their interesting pharmacological activities [3]. A series of chalcone derivatives bearing heterocycles [4] and synthesis of the heterocyclic chalcone in combination with antibiotics [5] were recorded. Most of the chalcones are highly biologically active with a number of pharmacological and medicinal applications [6]. Spiroindoline [7] and imidazoline derivatives [8] can be evaluated for their binding affinities and antagonistic activities at the neuropeptide YY5 receptor, as well as their good brain penetration. Also, spironolactone [9,10] is effective in treating mild hypertension without inducing hypokalemia or increased secretion of Aldosterone and Ephlerenone. Notably,
ketoconazole \[11,12\] has been successful as an antifungal agent. If the spiromimidazole derivatives \[13\] are combined with antibacterial agents (vancomycin, ciprofloxacin), it may be observed that antagonistic activity results from the competitive binding of the medicinal molecules into bacteria cells’ receptor. On the other hand, the isoxazolines \[14,15\] are evaluated for their in vitro antifungal activity and their proliferative response to human mononuclear peripheral blood cells. Imidazo-oxazole derivatives \[16\] can be synthesized via treatment of imidazole derivatives with oxirane, and they have been tested for anti-mycobacterial activity. The \((E)-4\)-aryl-4-oxo-2-butenoic acids are convenient poly electrophilic reagents for the addition reaction of nucleophiles; e.g., carbon, nitrogen, and sulfur occur exclusively at the \(\alpha\)-carbon electrophilic center of the carboxy precursors used for the synthesis of relevant heterocyclic compounds \[17–22\].

The authors have reported \[19,23\] that the behavior of \(4-(4\text{-acetyl amino/bromo phenyl})-4\text{-oxo-but-2-enoic acids (1)}\) toward the hydrogen peroxide in the presence of 8% sodium hydroxide/methanol afforded the epoxide products of \((E)-1-(4\text{-acetylaminobenzoyl})\)-2-oxirane carboxylic acids \(2\). Among them, imidazo[2,1-b]1,3,4-thiadiazole is an attractive aryl unit that causes a decrease in electron density (low HOMO) of the synthesized chalcones, which increases its antibacterial activity \[24\].

2. Results and Discussion

2.1. Chemistry

The regioselective reaction of \((E)-1-(aryl)-2\text{-oxirane carboxylic acids (2)}\) with 2-amino-5-aryl-1,3,4-thiadiazole in the presence of boiling ethanol afforded imidazo[2,1-b]thiadiazole derivatives \(3\) \[18,19\], via the \(N\)-alkylation of amino thiadiazole moieties that added to the activated \(\alpha\)-position of 3-membered heterocycle \[25\] of the carboxylic acids \(2\) (Scheme 1). Refluxing adducts \(3\) with drops of triethylamine [TEA] in boiling ethanol afforded the chalcone derivatives \(4\) in good yield. The geometrical isomerism of the compounds \(4\) can be detected only in \(^1\text{H}-\text{NMR} \) spectra. The \(^1\text{H}-\text{NMR}\) of the compound \(4a\) in DMSO reveals \(\delta\) ppm at 2.54 \((s, \text{CH}_3)\) corresponding to \(\text{CH}_2\text{CONH}\) precursor, multiplied by 7.48–7.86 corresponding to the aromatic protons; the proton of arylidine has two chemical shift values at 7.72, \(1\text{H}, s\), \(\text{CH}=\), arylidine, referring to the \(E\)-configuration, 82% (high integrated value (%)) in \(^1\text{H}-\text{NMR}\) reflects stability of \(E\)-isomer), and at 7.78, \(1\text{H}, s\), \(\text{CH}=\), arylidine, 18% in the form of a \(Z\)-configuration. The chemical shift \(\delta\) ppm of the arylidine proton of the \(Z\)-configuration was increased due to the field effect of the carbonyl moiety of the imidazole, and at 13.2, \(s\), acidic NH proton was exchangeable with \(\text{D}_2\text{O}\).

Scheme 1. Synthetic routes for compounds 2–4. (i) Reaction of the oxirane derivative 2 within 2-amino-1,3,4-thiadiazole in boiling ethanol afforded \(\alpha\)-hydroxy ketone 3; (ii) Refluxing the derivatives 3 in boiling ethanol/TEA, afforded chalcone derivatives 4 in good yield 60%–71%; (iii) Direct synthesis of the chalcone derivatives 4 in butanol/reflux 5 h, but in poor yield of 35%–40%.
An authentic reaction was done, when the acid 2 was submitted to react with 2-amino-5-aryl-1,3,4-thiadiazole in boiling butanol, which led to spontaneous dehydration of the adduct 3 to afford the more thermodynamically stable 4 (Scheme 1). The new chalcone product 4, the thermally labile acid 2 and/or substituted aminothiazoles were very sensitive to higher temperatures. The classical synthesis (Route iii) in Schemes 1 and 2 was not suitable because the prolonged (4–6 h) heating (110–120 °C) led to butanol yields lower than 40% and which tended to decrease. The novel chalcone derivative 4 can also be synthesized in one pot reaction, fusing the 2-aminothiazole, diethylxalate and 4-bromoacetophenone derivatives in pellet KOH, with a small amount of water (useless organic solvent) in MW irradiation (W 250 and T 150 °C) for 15 min, in line with eco-friendly environmental chemistry, afforded the chalcone derivative 4d, but also, it was formed with a poor yield of 40%.

Scheme 2 outlines the synthesis of the novel chalcone derivative 4d. Attempts to have favourable access to the desired chalcone using suitable base triethylamine [TEA] led to the decomposition of the reactive chalcone 4, when the authors used strong basic medium.

Scheme 2. Synthetic route for compound 4d. Reagents and Conditions: (i) ethanol/reflux 3 h, 74%; (ii) ethanol/TEA/reflux 5 h, good yield 60%–71%; (iii) Butanol/reflux 5 h, with a poor yield of 35%–40%; (iv) MW irradiation (W 250 and T 150 °C) for 15 min, with a poor yield of 35%–45%.

Chalcone bears a very good synthon so that varieties of novel heterocycles with good pharmaceutical profile can be designed [4–6]. An interesting feature of this structure is a pincer-like conformation of the molecule [26], and a reaction between isatin and the α-amino acid afforded the azomethine ylide, with regioselective addition to the C=C bond of aroylacrylic acid or chalcone. The electrophilic centers in 4 can be allowed to react with simply bi-nucleophiles, e.g., hydrazine and hydroxyl amine, to afford important spiro heterocyclic compounds [19]. Treatment of the isomers 4b, 4d, 4e and 4f with hydrazine hydrate and/or hydroxylamine (Scheme 3) afforded spiro heterocyclic compounds 5 and 6 via formation of the hydrazone and oxime intermediates 5i and 6i, respectively [19]. Moreover, when the chalcone derivatives 4 were allowed to react with the cyclopentanone in the presence of sodium hydroxide, this afforded 50% adducts 7 [27]. Treatment of the adduct 7 with acetic anhydride afforded spiro-pyrene derivative 8 instead of formation of the furan[3,2-α][1,3,4-thiadiazole][3,2-α]imidazole [19]. These reactions can be reflected in the reactivity of the carbonyl group of the aroyl moiety which is greater than the carbonyl group of imidazole moiety.

The authors reported that the product 8 can be changed and returned to 7 after approximately one day. The lower stability of the product 8 allowed the ring to open again and return to the product 7 due to the bridgehead spiro carbon atom that can be surrounded by four sp² atoms.

The procedure would include arrest of the reaction at the cycloalkane level and restart with different carbon nucleophiles. The authors expected that in the case of electron withdrawing groups
Molecules 2015, 20, 22069–22083

in the pyran structures, the best yields were attained by the direct procedure. As it is shown, the best yield in spiro-pyrane derivative 8 were achieved for the derivative 8a, which subsequently its chalcone 4a was the most commonly used in the continued research.

Scheme 3. Synthetic route for compounds 5–8. Reagents and Conditions: (i) NH$_2$NH$_2$/ethanol/reflux 6 h, 60%–65%; (ii) NH$_2$OH/pyridine/reflux 5 h, 55%–70%; (iii) Cyclopentanone/ethanol/NaOH(50%)/Stir, 65%–74%; (iv) Acetic anhydride/reflux 1 h, 35%–45%.

So, when the chalcone 4a was allowed to react with different carbon acids, e.g., ethylacetocetate, ethylcyanoacetate, diethylmalonate, acetylacetone, and malononitrile. The reaction can proceed with ethylacetocetate through the intermediate 9a followed by ring closure via the tetrahedral mechanism to afford the regioselective product 10 that can be confirmed by the lower stability of the product 11 (Scheme 4). The authors assumed this one-pot reaction would similarly work with ethylcyanoacetate and diethylmalonate that confirmed this fact through the cyclization of the intermediates 9b–c. In the same manner, the spiro-pyrane derivative 11 was alternatively substituted with R$^1$ and R$^2$ groups, they were synthesized in good yields from acetylacetone and/or malononitrile (the same bi-functional carbon acids). According to the proposed pathway, the use of a controlled sequential procedure for the preparation of spiro-pyrone 10 and spiro-pyrane 11 should give access to a wider series of spiro compounds 10 and 11, having different substituents R, R$^1$, and R$^2$.

Scheme 4. Synthetic route for compounds 9–11.
2.2. Antibacterial Activity Evaluation

Agar Diffusion Method

The obtained new compounds were screened in vitro for their antibacterial activities against Gram positive bacteria (Staphylococcus aureus (ATCC 25923) and Bacillus cereus (ATCC 10987)), Gram negative bacteria (Serratia marcescens (ATCC 274) and Proteus mirabilis (SM514)), using the agar diffusion technique. The results of the antibacterial activity tests are shown in Table 1.

Table 1. Antibacterial activity of the synthesized compounds: Agar diffusion method.

| Compound No. | Gram Positive | Gram Negative |
|--------------|---------------|---------------|
|              | Staphylococcus aureus | Bacillus cereus | Serratia marcescens | Proteus mirabilis |
| 4a           | +++           | ++            | +++           | ++            |
| 4b           | +++           | ++            | +++           | ++            |
| 4c           | +++           | +++           | +++           | +++           |
| 4d           | +++           | ++            | +++           | ++            |
| 4e           | ++            | +             | +             | +             |
| 4f           | +++           | +++           | ++            | +++           |
| 6a           | ++            | +             | +             | +             |
| 6b           | ++            | ++            | ++            | +             |
| 7a           | ++            | ++            | +++           | +             |
| 7b           | ++            | ++            | +++           | +             |
| 8a           | –             | +             | –             | –             |
| 8b           | +             | +             | +             | +             |
| 9a           | ++            | ++            | +++           | +++           |
| 9b           | ++            | +++           | +++           | ++            |
| 10a          | +             | +             | +             | +             |
| 10b          | +             | +             | +             | +             |
| Chloramphenicol® | +++           | +++           | +++           | +++           |
| Ampicillin®   | +++           | +++           | +++           | +++           |

The width of the zone of inhibition indicates the potency of antibacterial activity; (−) no antibacterial activity (0%–25%); (+) mild activity with the diameter of the zones equal to 0.5–0.8 cm (25% dehydroascorbate 40%); (+++) marked high activity with the diameter of the zones equal to 1.8–2.0 cm (85%–100%).

Most of the synthesized compounds were found to possess some antibacterial activity towards all the microorganisms used. Compounds 4, 6, 7, 9 possess the highest antibacterial activities because they have been 65%–95% inhibition zone for antibacterial activity for both gram positive and gram negative bacteria.

The generated QSAR model [24] indicates that a minimum HOMO energy of more than 30 chalcone derivatives contributes positively to the antibacterial activity. Electron-withdrawing substituents are lower the HOMO energy, such as halogens, due to the inductive effect of halogen which results in the decrease in electron density from the σ space of benzene ring, particularly o-chloro derivatives, thereby decreasing the energy of HOMO [28]. Designing chalcone derivatives with a high degree of bonding linearity (κ2 index) with groups that increase molecular weight (high value of ADME Weight) represents a positive contribution to the antibacterial activity [24]. P-glycoprotein (P-gp) is an ATP-dependent multidrug resistance efflux transporter that plays an important role in anticancer drug resistance and in the pharmacokinetics of medicines [29]. The bio-isostere of aroyl vinylamide and the new synthetic compound 4 indicated antitumor activities, as well as tyrosine kinase inhibition [30]. So, the authors wanted to synthesize unsymmetrical heterocyclic chalcone derivatives possessing imidazo-thiadiazole moiety, considered as antibacterial agents [16], with high molecular weight and electron withdrawing groups (low HOMO values); e.g., o-halo aryl and 2-amino-1,3,4-thiazole precursors and the characteristic linearity of bonding patterns (high κ2) that exhibit high antibacterial activity, c.f. Tables 1 and 2 and Figures 1 and 2. The authors explained that the strongest activities of the synthetic compounds 4c
and 4f (Table 1) were due to the inductive effect of the 2-chloro derivatives that decreases the electron density (decreased HOMO values), as shown in Figure 1B,D and increases the antibacterial activity. But the 4-chloro derivatives have electromeric effects that increase the electron density (increased HOMO) and decrease activity, as shown in Figure 1A,C. Also, the results are shown in Table 2, screen the Minimum Inhibitory Concentration (MIC) and calculated values of ADME, HOMO, and κ2 that are used to generate the QSAR model. The effect of amino-1,3,4-thiazole precursors were stronger than pyridyl and nitrophenyl precursors [24] that outlined the strong antibacterial activity of the synthesized compounds (Table 2).

![Figure 1](image1.png)

**Figure 1.** Outlines the electron distribution in HOMO for 4e (A); 4f (B); 4b (C) and 4c (D) compounds, respectively, are outlined, confirming that electron density is low among the o-chloro derivatives (decreased HOMO and increased activity). Electron deficient at the center of molecule means increase the antibacterial activity as the compounds 4f (B) and 4c (D).

![Figure 2](image2.png)

**Figure 2.** Outlines the ring B in a blue circle that contains three electronegative nitrogen atoms, a carbonyl group and a halogen atom. These elements decrease the HOMO value and increase activity. Red circle outline aryl vinyl amide structure isostere for synthesized chalcones 4.
On the other hand, the resistance mechanism to penicillin antibiotics in these bacteria is the expression of beta-Lactamase enzyme. In order to use the penicillin antibiotics which are still effective against them, Jaramillo et al. [31] had evaluated many chalcones as inhibitors of this enzyme. The chalcone derivatives 4 exhibit high antibacterial activity due to the presence of activated double bond as capping agent for the enzyme, means the chalcones as a possible drug (enzyme inhibitor). Also, the spiro compounds 6 exhibit high antibacterial activity [32–34] as compared with compounds 5 and 10, because of the spiro five membered rings is near to structure of penicillin core (β-lactam-thiazole ring) and so they can be matching with the enzyme more than compounds 10. Compounds 5 have an acidic NH group of pyrazole precursor and so they have less fitting with enzyme. On the other hand, the compounds 7, and 9 exhibit high antibacterial activity due to the presence of the carbonyl groups that condensed with NH₂-E (enzymatic inhibitor).

Table 2. Rationalization of the synthesized Chalcones 4 as antibacterial agents using quantum chemical computation.

| Comp. Ref. | Substituent Ring A | Substituent Ring B | MIC a (μg/mL) | ADME b Weight | HOMO b | κ2 Index b |
|------------|--------------------|--------------------|---------------|---------------|--------|------------|
| 4a         | NHCOCH₃            |                    | 600           | 320.3         | −11.864 | 8.762      |
| 4b         | NHCOCH₃            |                    | 700           | 253.6         | −10.282 | 9.163      |
| 4c         | NHCOCH₃            |                    | 500           | 393.1         | −13.409 | 9.718      |
| 4d         | Br                 |                    | 600           | 314.3         | −11.940 | 7.415      |
| 4e         | Br                 |                    | 700           | 225.2         | −11.322 | 7.505      |
| 4f         | Br                 |                    | 500           | 275.3         | −13.918 | 8.914      |
| 6 [24]     | H                  |                    | 600           | 321.3         | −9.752  | 8.590      |
| 9 [24]     | H                  |                    | 700           | 277.29        | −9.509  | 7.513      |

* a Minimum Inhibitory Concentration; b Calculated values used to generate QSAR models.

3. Experimental Section

3.1. General Information

All melting points are corrected and determined on a stuart electric melting point apparatus (Microanalytical centre, ainshams university, Cairo, Egypt). Elemental analyses were carried out by Elementar Viro El-Microanalysis at the Micro-analytical Center, National Research Center, Egypt. IR spectra (KBr) were recorded on infrared spectrometer FT-IR 400D (New York, NY, USA) using OMNIC program and are reported frequency of absorption in terms of cm⁻¹ and ¹H-NMR spectra recorded on a Bruker spectrophotometer (Rheinstetten, Germany) at 400 MHz using TMS as internal standard and with residual signals of the deuterated solvent δ = 7.26 ppm for CDCl₃ and δ 2.51 ppm for DMSO-d₆. ¹³C-NMR spectra were recorded on the same spectrometer (Rheinstetten, Germany) at 100 MHz and referenced to solvent signals δ = 77 ppm for CDCl₃ and δ 39.50 ppm for DMSO-d₆. DEPT 135 NMR spectroscopy were used where appropriate to aid the assignment of signals in the ¹H- and ¹³C-NMR spectra. The mass spectra were recorded on Shimadzu GCMS-QP-1000 EX mass
spectrometer (Kyoto, Japan) used the electron ionization technique at 70 e.v. Homogeneity of all synthesized compounds was checked by TLC.

3.2. General Procedure for Synthesis of the Compounds 2, 3, 5a and 5c are in the Literature [19]

3.3. General Procedure for Synthesis of the Compounds 4a–f

Fuse the compounds 3a–f (0.01 mol) and 3–5 drops triethyl amine (TEA) in oil bath for 5 min, then refluxing in 50 mL of boiling aqueous ethanol for 5 h. The solid was separated after cooling and the pH of the solution was 6.5. The crude products were filtered, washed by petroleum ether (b.p. 40–60 °C), dried and then recrystallized from dioxane.

\[(E)-N-(4-(2-(5-Oxo-2-phenylimidazo[2,1-b]1,3,4-thiadiazol-6(5H)ylidine)acetyl)phenyl)acetamide (4a).\]

Yield 2.35 g (60%), light yellow finely crystalline, m.p. 176–178 °C, IR (KBr), ν, cm⁻¹: 3245 (NH), 1706, 1670, 1650 (CO), 1613 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 2.54 (3H, s, CH₃), 7.72 (1H, s, CH=, arylidine, 82% in form of E-configuration), 7.78 (1H, s, CH=, arylidine, 18% in form of Z-configuration), 7.48–7.86 (9ArH, m, aromatic protons), 13.2 (1H, s, acidic NH proton which exchanged in D₂O), ¹³C-NMR δ, ppm (CH₃CO), 40.0 (CH₃CO), 105.4 (C₆H₄, Ph), 110.6 (C₆H₅, 1.25 (C₆H₅), 142.3 (C₆H₅, 1.44 (CH=), 147.4 (C₂ Ar), 148 (C₆ H ), 150.2 (C=CH), 152.4 (C₁ Ph), 154.5 (C₁ Ar), 156.0 (CNS), 162.2 (CN₂S), 165.1 (CO imidaz., 168.0 (CO amide), 190.2 (CO ketone), and found, %: C 61.50, H 3.59, N 14.30, S 8.19 for C₂₀H₁₄N₄O₂SCl. Calculated, %: C 61.53, H 3.61, N 14.35, S 8.21; MS: m/z 346 [M+ - CH₂=CO], 347 [M+ 1] [imidazolothiadiazole moiety].

\[(E)-N-(4-(2-(4-Chlorophenyl-5-oxo-imidazo[2,1-b]1,3,4-thiadiazol-6(5H)ylidine)acetyl)phenyl)acetamide (4b).\]

Yield 2.68 g (63%), yellow finely crystalline, m.p. 198–200 °C, IR (KBr), ν, cm⁻¹: 3245 (NH), 1710, 1691, 1655 (CO); 1630 (C=N; ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 2.06 (3H, s, CH₃), 7.73 (1H, s, CH=, arylidine, 78% in form of E-configuration), 7.81 (1H, s, CH=, arylidine, 22% in form of Z-configuration), 7.44–7.83 (8ArH, m, aromatic protons), 12.6 (1H, s, acidic NH proton which exchanged in D₂O), ¹³C-NMR δ, ppm (CH₃CO), 22.5 (CH₃CO), 121.2 (C₂ Ph), 128.8 (C₆H₅, Ph), 129.5 (C₁ Ar), 131.5 (C₆H₅, PhCl), 132.3 (C₆H₅, 134.6 (CH=), 137.1 (C₂ Ar), 138.3 (C₆ H ), 140.2 (C=CH), 142.0 (C₂ Ph), 144.2 (C₁ Ar), 160.3 (CNS), 161.4 (CN₂S), 166.5 (CO imidaz.), 167.4 (CO amide), 191.0 (CO ketone) and found, %: C 56.53; H 3.06; N 13.16, Cl 8.30, S 7.53 for C₂₀H₁₃N₄O₂SCl. Calculated, %: C 56.54, H 3.08, N 13.19, Cl 8.34, S 7.55.

\[(E)-N-(4-(2-(2-Chlorophenyl-5-oxo-imidazo[2,1-b]1,3,4-thiadiazol-6(5H)ylidine)acetyl)phenyl)acetamide (4c).\]

Yield 2.68 g (63%), yellow finely crystalline, m.p. 198–200 °C, IR (KBr), ν, cm⁻¹: 3245 (NH), 1710, 1691, 1655 (CO); 1630 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 2.06 (s, 3H, CH₃), 7.69 (1H, s, CH=, arylidine, 80% in form of E-configuration), 7.77 (1H, s, CH=, arylidine, 20% in form of Z-configuration), 7.44–7.83 (8ArH, m, aromatic protons), 12.4 (1H, s, acidic NH proton which exchanged in D₂O), and found, %: C 56.50, H 3.02, N 13.11, Cl 8.30, S 7.51 for C₂₀H₁₃N₄O₂SCl. Calculated, %: C 56.54, H 3.08, N 13.19, Cl 8.34, S 7.55; MS: m/z 346 [M+ - CH₂=CO], 347 [M+ 1] [imidazolothiadiazole moiety].

\[(E)-6-(4-Bromophenyl)-2-oxothidilidazo[2,1-b]1,3,4-thiadiazol-5(6H)-one (4d).\]

Yield 2.72 g (66%), yellow powder, m.p. 152–154 °C, IR (KBr), ν, cm⁻¹: 1694, 1672 (CO), 1613 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 7.70 (1H, s, CH=, arylidine, 86% in form of E-configuration), 7.79 (1H, s, CH=, arylidine, 14% in form of Z-configuration), 7.44–7.73 (9ArH, m, aromatic protons). ¹³C-NMR δ, ppm (CH₃CO), 119.6 (C₆H₅, Ph), 127.6 (C₆H₅, Ph), 130.5 (C₆H₅, Ph), 132.7 (C₆H₅, Ar), 135.3 (C₂₀ H ), 137.6 (C₁ Ph), 139 (CH=), 141.2 (C₂ Ar), 142.1 (C₁ Ar), 145.5 (C=SO), 149.7 (CNS), 155.3 (CN₂S), 166.8 (CO imidaz.), 179.2 (CO) and found, %: C 52.50; H 2.35; N 10.15. C₁₈H₁₀N₃O₂BrS. Calculated, %: C 52.42, H 2.42, N 10.19. MS: m/z 378 [M+ - CO], 335 [M+ - Ph], 263 [M+ - Ph(Br)], 138 [imidazolothiadiazole moiety].
E-configuration), 7.80 (1H, s, CH=, arylidine, 22% in form of Z-configuration), 7.60–7.83 (8ArH, m, aromatic protons), and found, %: C 48.30, H 2.10, N 9.33. C_{18}H_{9}N_{3}O_{2}BrClS. Calculated, %: C 48.37, H 2.15, N 9.40.

(E)-6-(4-Bromophenyl)-2-oxoethylidene)-2-(2-chlorophenyl)imidazo[2,1-b]1,3,4-thiadiazol-5(6H)-one (4f).

Yield 3.04 g (68%), yellow finely crystalline, m.p. 180–182 °C. IR (KBr), υ, cm⁻¹: 1708, 1684 (CO); 1630 (C=N). 1H-NMR (DMSO-δ_{6}), δ, ppm, (J, Hz): 7.73 (1H, s, CH=, arylidine, 73% in form of E-configuration), 7.84 (1H, s, CH=, arylidine, 27% in form of Z-configuration), 7.72–7.86 (8ArH, m, aromatic protons), and found, %: C 48.35, H 2.15, N 9.35 for C_{18}H_{9}N_{3}O_{2}BrClS. Calculated, %: C 48.37, H 2.15; N 9.40.

3.4. General Procedure for Synthesis of the Compounds 5b, 5d, and 5e

A mixture of chalcone derivatives 4b, 4d and 4e (5 mmol) and hydrazine hydrate (0.5 mL, 0.01 mol) in boiling ethanol (50 mL) was heated under reflux for 5 h. The reaction mixture was allowed to cool and the product was filtered, dried, and recrystallized from the benzene and/or ethanol.

N-(4-(2-(2-Chlorophenyl)-5-oxo)-2',4'-dihydro-5H-spiroimidazo[2,1-b]1,3,4-thiadiazol-6,3'-pyrazol]-5'-yl)phenyl)acetamide (5b). Yield 1.43 g (65%), off white crystal, m.p. 164–166 °C. IR (KBr), υ, cm⁻¹: 3420 (NH); 1671, 1640 (CO); 1619, 1570 (C=N). 1H-NMR (DMSO-δ_{6}), δ, ppm, (J, Hz): 1.2 (2H, d, CH2, J = 5.4); 2.5 (3H, s, CH3); 7.0–8.71 (8H, m, Ar-H); 12.40 (1H, br, s, NH of acetamide moiety), 13C-NMR δ, 22.3 (CH3CO); 69.6 (CH2C=N); 122.4 (C4 Ph), 126.8 (C3,5 Ph), 129.1 (C Spiro), 131.5 (C3 Ar), 131.8 (C3 Ar), 132.6 (C2,6 Ph), 137.4 (C2 Ar), 138 (C6 Ar), 140.2 (C4 Ar), 144.5 (C1 Ar), 145.1 (C1 Ph), 158.0 (C=N), 161.3 (CNS), 163.2 (CN2S), 165.3 (CO imidaz.), and found, %: C 54.70, H 3.42, N 19.10, Cl 8.02, S 7.27 for C_{20}H_{15}N_{6}O_{2}CIS. Calculated, %: C 54.73, H 3.45, N 19.15, Cl 8.08, S 7.30.

5'- (4-Bromophenyl)-2-phenyl-2',4'-dihydro-5H-spiroimidazo[2,1-b]1,3,4-thiadiazol-6,3'-pyrazol]-5-one (5d). Yield 1.28 g (60%), White finely crystalline, m.p. 138–140 °C. IR (KBr), υ, cm⁻¹: 3423, 3151 (NH), 1671, 1640 (CO); 1H-NMR (DMSO-δ_{6}), δ, ppm, (J, Hz): 1.2 (2H, d, CH2, J = 5.5); 2.5 (3H, s, CH3); 5.4 (1H, s, NH), 7.0–7.81 (9H, m, Ar-H); 13C-NMR δ, 69.4 (CH2C=N), 122.1 (C4 Ph), 125.9 (C3,5 Ph), 127.1 (C Spiro), 131.4 (C3 Ar), 131.8 (C3 Ar), 132.5 (C2,6 Ph), 136.8 (C2 Ar), 137.4 (C6 Ar), 140.2 (C4 Ar), 144.5 (C1 Ar), 145.1 (C1 Ph), 158.0 (C=N), 161.3 (CNS), 163.2 (CN2S), 165.3 (CO imidaz.), and found, %: C 50.70, H 2.81, N 16.40, Br 18.71, S 7.50 for C_{18}H_{12}N_{5}OBrS. Calculated, %: C 50.72, H 2.84, N 16.43, Br 18.74, S 7.52.

5'- (4-Bromophenyl)-2-(4-chlorophenyl)-2',4'-dihydro-5H-spiroimidazo[2,1-b]1,3,4-thiadiazol-6,3'-pyrazol]-5-one (5e). Obtained similarly to compound 5a from compound 4f (2.23 g, 5 mmol). Yield 1.50 g (65%), white finely crystalline, m.p. 150–152 °C. IR (KBr), υ, cm⁻¹: 3423, 3333 (NH); 1680, 1648 (CO); 1H-NMR (DMSO-δ_{6}), δ, ppm, (J, Hz): 1.4 (2H, d, CH2, J = 5.4); 2.5 (3H, s, CH3); 5.4 (1H, s, NH), 7.0–7.81 (8H, m, Ar-H); found, %: C 46.89, H 2.40, N 15.20, Br 17.32, Cl 7.67, S 6.92 for C_{18}H_{10}N_{5}OBrS. Calculated, %: C 46.92, H 2.41, N 15.20, Br 17.34, Cl 7.69, S 6.95; MS: m/z 464 [M⁺ + 2]; 461 [M⁺]; 418 [M⁺ – CH2=CH=]; 194 [spiro moiety].

3.5. General Procedure for Synthesis of the Compounds 6a–d

A mixture of 4a, 4b, 4d and/or 4f (5 mmol) and hydroxyl amine hydrochloride (0.52 g; 7.5 mmol) in boiling pyridine (25 mL) was heated under reflux for 6 h. The reaction mixture was allowed to cool, poured into ice/HCl until pH of the solution is 6.5, and the product was filtered, dried, and recrystallized from ethanol.

N-(4-(5-Oxo-2-phenyl-2',4'-dihydro-5H-spiroimidazo[2,1-b]1,3,4-thiadiazol-6,5'-isoxazol]-3'ylphenyl)acetamide (6a). Yield 1.11 g (55%), white finely crystalline. m.p. 197–200 °C. IR (KBr), υ, cm⁻¹: 3425 (NH), 1647 (CO), 1630 (C=N); 1H-NMR (DMSO-δ_{6}), δ, ppm, (J, Hz): 2.5 (3H, s, CH3), 3.59 (2H, d,
N-(4-(2-(4-Chlorophenyl)-5-oxo-2',4'-dihydro-5H-spiroimidazo[2,1-b]1,3,4-thiazadiazol-6,5'-isoxazolyl)phenyl)acetamide (6b). Yield 1.47 g (67%), white finely crystalline powder, m.p. 192–195 °C. IR (KBr) ν, cm⁻¹: 3271 (NH), 1660 (CO), 1631 (C=η). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 2.3 (3H, s, CH₃), 3.20 (2H, d, CH₂, J = 5.7), 7.53–7.96 (10H, m, Ar-H); ¹³C-NMR (DMSO), δ, ppm: 21.7 (CH₃CO), 66.6 (CH₂C=N), 119.7 (C spiro), 126.8 (C₃, Ar), 128.3 (C₃, PhCl), 130.5 (C₂, PhCl), 134.5 (C₂, Ar), 136.9 (C₄ PhCl), 138.2 (C₁ Ar), 140.2 (C₁ Ph), 143.5 (C₁ PhCl), 147.1 (C₁ N=), 161.3 (CNS), 164.0 (CNS₂), 166.4 (CO imidaz.), 168.0 (CO amide), and found, %: C 54.58, H 3.19, N 15.88, CI 8.02, S 7.27 for C₃₂H₂₅N₃O₅S₁₃C₂₁. Calculated, %: C 54.61, H 3.21, N 15.92, Cl 8.06, S 7.29.

3'-(4-Bromophenyl)-2-phenyl-4'H,5H-spiroimidazo[2,1-b]1,3,4-thiazadiazol-6,5'-isoxazolyl)-5-one (6c). Yield 1.56 g (70%), white finely crystalline powder, m.p. 197–200 °C. IR (KBr) ν, cm⁻¹: 3425 (NH); 1630 (C=N). ¹H-NMR (DMSO-d₆) δ, ppm, (J, Hz): 2.3 (3H, s, CH₃), 7.53–7.96 (10H, m, Ar-H). ¹³C-NMR (DMSO), δ, ppm: 65.8 (CH₃), 111.2 (C spiro); 116.2 (C₃, Ph); 120.9 (C₃, Ph); 124.6 (C₂, Ar); 132.7 (C₂, Ph); 134.3 (C₄ Ph); 136.3 (C₄ PhBr), 139.2 (C₁ PhBr), 140.6 (C₁ Ph), 153.0 (C=N), 157.2 (CNS), 162.3 (CNS₂), and found, %: C 50.60, H 2.58, N 13.12, Br 18.68, S 7.48 for C₁₈H₁₁N₄O₂BrS. Calculated, %: C 50.60, H 2.60, N 13.11, Br 18.70, S 7.50.

3'-(4-Bromophenyl)-2-(2-chlorophenyl)-4'H,5H-spiroimidazo[2,1-b]1,3,4-thiazadiazol-6,5'-isoxazolyl)-5-one (6d). Yield 1.39 g (58%), white finely crystalline powder, m.p. 192–195 °C. IR (KBr) ν, cm⁻¹: 3271 (NH), 1680 (CO), 1631 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 3.49 (2H, br. s, CH₂), 7.53–7.96 (10H, m, Ar-H); found, %: C 46.85, H 2.16, N 12.11, Br 17.29, S 6.92 for C₁₈H₁₁N₄O₂BrS. Calculated, %: C 46.82, H 2.18, N 12.13, Br 17.31, S 6.94.

3.6. General Procedure for Synthesis of the Compounds 7a-c

A mixture of 4a, 4b and/or 4d (5 mmol), cyclopentanone (0.45 mL, 5 mmol), (50%) NaOH (5 mL) and ethanol (25 mL) was refluxed for 3 h, and left overnight for 3 days. The reaction mixture was poured into ice/HCl, until pH of the solution becomes 6.5. The crude product was filtered, washed by petroleum ether (b.p. 40–60 °C), and then crystallized from benzene.

N-(4-(2-(5-Oxo-6-(3-oxocyclopentyl)-2-phenyl-5,6-dihydroimidazo[2,1-b]1,3,4-thiazadiazol-6-yl)acetyl)phenyl)acetamide (7a). Yield 1.57 g (65%), white finely crystalline powder, m.p. 176–178 °C. IR (KBr) ν, cm⁻¹: 3245 (NH); 1685, 1670, 1650 (CO), 1613 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 1.12 (6H, m, 3CH₂), 2.02 (1H, dd, H-cyclopent); 2.36 (3H, s, CH₃); 2.50 (2H, s, CH₂CO); 7.44–7.73 (9ArH, m, aromatic protons); 13.2 (1H, s, acidic NH proton which exchanged in D₂O) and found, %: C 63.25; H 4.65, N 11.79, S 6.77 for C₂₅H₂₅N₄O₂S. Calculated, %: C 63.28, H 4.67, N 11.81, S 6.76. MS: m/z 474; 432 [M⁺ – CH₂=C=O]; 141 (imidazolothiadiazole moiety).

N-(4-(2-(2-Chlorophenyl)-5-oxo-6-(3-oxocyclopentyl)-5,6-dihydroimidazo[2,1-b]1,3,4-thiazadiazol-6-yl)acetyl)phenylacetamide (7b). Yield 1.88 g (74%), white finely crystalline. m.p. 210–212 °C. IR (KBr), ν, cm⁻¹: 3245 (NH); 1710, 1691, 1655 (CO); 1630 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 1.2 (6H, m, 3CH₂), 2.02 (1H, dd, H-cyclopent); 2.47 (3H, s, CH₃); 2.51 (2H, s, CH₂CO); 7.44–7.83 (8ArH, m, aromatic protons); 8.2 (1H, s, acidic NH proton which exchanged in D₂O); ¹³C-NMR (DMSO), δ, ppm: 22.4 (CH₃CO); 31.8 (C₃, cyclopent); 57.2 (C₅ cyclopent); 67.8 (CH₂CO spiro); 109.3 (C₂, CH, cyclopent); 119.6 (C₃, Ar⁺); 122.2 (C spiro); 124.3 (C₃, Ar⁺); 131.7 (C₂, Ar⁺); 135.5 (C₂, Ar⁺); 141.5 (C₁ Ar⁺), 143.4 (C₁ Ar), 144.1 (C₁ Ar), 152.6 (C₁ Ar), 161.0 (CNS), 164.0 (CNS₂), and found, %: C 63.25; H 4.65, 11.79, S 6.77 for C₂₅H₂₅N₄O₂S. Calculated, %: C 63.28, H 4.67, N 11.81, S 6.76. MS: m/z 474; 432 [M⁺ – CH₂C=O]; 141 (imidazolothiadiazole moiety).

6-(2-(4-Bromophenyl)-2-oxoethyl)-2-(2-chlorophenyl)-6-(3-oxocyclopentyl)imidazo[2,1-b]1,3,4-thiazadiazol-5-(6H)-one (7c). Yield 1.83 g (70%), white finely crystalline. m.p. 196–198 °C. IR (KBr), ν, cm⁻¹:
Molecules 2015, 20, 22069–22083

3245 (NH); 1710, 1691, 1655 (CO); 1630 (C=N). 1H-NMR (DMSO-d6), δ, ppm, (J, Hz): 1.2 (6H, m, 3CH2), 2.08 (1H, dd, H-cyclohex.), 2.32 (3H, s, CH3), 2.53 (2H, s, CH2CO), 7.62–7.83 (8ArH, m, aromatic protons), 8.2 (1H, s, acidic NH proton which exchanged in D2O); And found, %: C 52.05; H 3.25; N 7.93, Br 15.03, Cl 6.66, S 6.00 for C23H17N3O3BrClS. Calculated, %: C 52.04, H 3.23; N 7.92, Br 15.05, Cl 6.68, S 6.03; MS: m/z 531 [M+ + 2], 529 [M+] 170; 139.

3.7. General Procedure for Synthesis of the Compounds 8a-c

A mixture of 7a (1.2 g, 2.5 mmol) and acetic anhydride (5 mL, 50 mmol) was refluxed in water bath for 2 h. The excess acetic anhydride was removed by fractional distillation and the separated product was filtered, dried and recrystallized from a mixture of toluene–ethanol.

N-(4-((5’-Oxo-2’-phenyl-6,7-dihydro-5H,5’H-spirocyclopenta[blpyran-4,6’-imidazo[2,1-b][1,3,4]thiadiazol]-2-yl)phenyl)acetamide (8a). Yield 502 mg (45%), white powder. m.p. 140–142 °C. IR (KBr), ν, cm−1: 3245 (NH); 1646, 1668 (CO); 1613 (C=N). 1H-NMR (DMSO-d6), δ, ppm (J, Hz): 1.43 (6H, m, 3CH2), 2.5 (3H, s, CH3), 6.7 (1H, s, pyrane-H), 7.44–7.73 (9ArH, m, aromatic protons); 13.2 (1H, s, acidic NH proton which exchanged in D2O), and found, %: C 65.75, H 4.40, N 12.25, S 7.00 for C23H19N3O3S. Calculated, %: C 65.77, H 4.42, N 12.27, S 7.02; MS: m/z 456 [M+] , 337 [M+ – PhCNO], 141 [imidazolo-thiadiazole moiety].

N-(4-((2’,4’-Clorophenyl)-5’-oxo-6,7-dihydro-5H,5’H-spirocyclopenta[blpyran-4,6’-imidazo[2,1-b][1,3,4]thiadiazol]-2-yl)phenyl)acetamide (8b). Yield 516 mg (39%), white powder. m.p. 172–174 °C. IR (KBr), ν, cm−1: 3245 (C=N), 1645, 1670 (CO), 1630 (NH). 1H-NMR (DMSO-d6), δ, ppm (J, Hz): 1.37 (6H, m, 3CH2); 2.06 (3H, s, CH3), 6.6–6.7 (s,1H, pyrane), 7.44–7.83 (8ArH, m, aromatic protons), 8.2 (1H, s, acidic NH proton which exchanged in D2O), found, %: C 61.13, H 3.88, N 11.43, Cl 7.20, S 6.50 for C23H19N3O3ClS. Calculated, %: C 61.16, H 3.90, N 11.41, Cl 7.22, S 6.53; MS: m/z 490 [M+], 377 [M+ – PhCl], 170, 140.

2-(4-Bromophenyl)-2’-(4-Chlorophenyl)-5’-oxo-6,7-dihydro-5H,5’H-spirocyclopenta[blpyran-4,6’-imidazo[2,1-b][1,3,4]thiadiazol]-5’-one (8c). Yield 420 mg (35%), white, finely crystalline powder; m.p. 236–238 °C. IR (KBr), ν, cm−1: 3245 (NH), 1672 (CO), 1630 (C=N); 1H-NMR (DMSO-d6), δ, ppm (J, Hz): 1.28 (8H, m, 4CH2), 6.6–6.7 (1H, s, pyrane), 7.44–7.83 (8ArH, m, aromatic protons), and found, %: C 53.85, H 2.95; N 8.19, Br 15.56, Cl 6.90, S 6.23 for C23H15N3O3BrClS. Calculated, %: C 53.87, H 2.95, N 8.19, Br 15.58, Cl 6.91, S 6.26; MS: m/z 511 [M+].

3.8. General Procedure for Synthesis of the Compounds 9a-c

A mixture of 4a (3.91 g, 0.01mol), and carbon acids e.g. ethylacetatoacetate, ethylcyanoacetate, diethylmalonate, acetylacetone, malononitril (0.01 mol), (50%) NaOH (8 mL) and ethanol (50 ml), was made and left overnight for 3 days. The reaction mixture was poured into ice/HCl, the crude product was filtered and washed by petroleum ether (b.p. 40–60 °C), and then crystallized from ethanol.

Ethyl 2-(6-(2-(4-acetamidophenyl)-2-oxoethyl)-5-oxo-2-phenyl-5,6-dihydroimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-3-oxobutanoate (9a). Yield 2.08 g (40%), white finely crystalline, m.p. 180–182 °C. IR (KBr), ν, cm−1: 3245 (NH), 1742, 1671, 1655 (CO), 1630 (C=N). 1H-NMR (DMSO-d6), δ, ppm, (J, Hz): 1.21 (3H, t, CH3), 2.32–2.34 (6H, s, 2CH3), 2.47 (2H, s, CH2CO), 4.23 (2H, q, CH2CO), 5.3 (1H, s, methine), 7.62–7.83 (9ArH, m, aromatic protons), 11.2 (1H, s, acidic NH proton which exchanged in D2O); And found, %: C 59.93, H 4.62, N 10.72, S 6.14 for C26H24N4O6S. Calculated, %: C 59.99, H 4.65, N 10.76, S 6.16; MS: m/z 520 [M+] , 170, 139.

Ethyl 2-(6-(2-(4-acetamidophenyl)-2-oxoethyl)-5-oxo-2-phenyl-5,6-dihydroimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-2-cyanoacetate (9b). Yield 1.87 g (37%), white finely crystalline, m.p. 164–166 °C. IR (KBr), ν, cm−1: 3331, 3245 (NH), 1734, 1670, 1645 (CO), 1630 (C=N). 1H-NMR (DMSO-d6), δ, ppm, (J, Hz): 1.23 (3H, t, CH3), 2.52 (3H, s, CH3), 2.47 (2H, s, CH2CO), 4.09 (2H, q, CH2CO), 5.1 (1H, s, methine),
N-(4-(2-[(4-acetamidophenyl)-2-oxoethyl]-5-oxo-2-phenyl-5,6-dihydroimidazo[2,1-b][1,3,4]thiadiazol-6-yl)phenyl)acetamide (9d). Obtained similarly to compound 9a, from compound 4a (3.91 g, 0.01 mol) and acetylacetone (1.05 mL, 0.01 mol). Crystallized from benz-ethanol. Yield 2.94 g (60%), white powder. m.p. 158–160 °C. IR (KBr) ν, cm⁻¹: 3245 (NH), 1670, 1645 (CO), 1630 (C=N). ¹H-NMR (DMSO-d₆), δ, ppm, (J, Hz): 2.32–2.46 (9H, br. s, 3CH₃), 2.47 (2H, s, CH₂CO), 4.45 (4H, q, CH₂CO), 5.6 (1H, s, methine), 7.62–7.83 (9ArH, m, aromatic protons), 11.2 (1H, s, acidic NH proton which exchanged in D₂O), and found, %: C 58.86, H 4.72, N 10.15, S 5.79 for C₂₇H₂₆N₄O₅S. Calculated, %: C 60.70, H 3.79, N 11.75, S 6.76 for C₂₇H₂₆N₄O₅S.

3.9. General Procedure for Synthesis of the Compounds 10a–c and 11a–d

The adduct 9 (1.9 mmol) was fused in oil bath for 1 h. The reaction mixture was poured into ice, the crude product filtered and washed by petroleum ether (b.p. 40–60 °C), and then crystallized.
Ethyl 6′-(4-acetamidophenyl)-2′,5-dioxo-2-phenyl-2′,3′-dihydro-5H-spiro[imidazo[2,1-b][1,3,4]thiadiazole-6,4′-pyran]-3′-carboxylate (10c). Yield 1.17 g (85%), white finely crystalline, m.p. 162–164 °C. IR (KBr), \(\nu\) cm\(^{-1}\): 3245 (NH), 1752, 1738, 1670, 1650 (CO), 1613 (C=N). \(^1\)H-NMR (DMSO-\(d_6\)), \(\delta\) ppm (J, Hz): 1.2 (2H, t, CH\(_2\)), 2.5 (3H, s, CH\(_3\)), 4.11 (2H, q, CH\(_2\)O), 4.4 (1H, s, CH(CO\(_2\)))\(_2\)), 6.2 (1H, s, PyH), 7.44–7.73 (9ArH, m, aromatic protons); 13.2 (1H, s, acidic NH proton which exchanged in D\(_2\)O); found, %: C 59.50, H 3.95, N 11.08, S 6.32 for C\(_{25}\)H\(_{26}\)N\(_4\)O\(_5\)S.

**Acknowledgments:**
The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at EPRI, Cairo and Ain Shams Universities for their cooperation in this research.

**Author Contributions:** The listed authors contributed to this work as described in the following.

Maher A. El-Hashash established the concepts of the work, and interpreted the results, Sameh A. Rizk, carried out the synthetic work, interpreted the results and prepared the manuscript, and Saad R. Atta-Allah carried out the synthetic work, and cooperated in the preparation of the manuscript. All authors read and approved the final manuscript.

4. Conclusions

In the present work, a series of novel chalcone and the spiro heterocyclic derivatives 4–11 were synthesized using 4-Aryl-4-oxo-2-butenioic acids 1a-b as starting materials. The structures of the new compounds were elucidated using IR, \(^1\)H-NMR, \(^{13}\)C-NMR and mass spectroscopy. Some of the newly synthesized compounds were screened against bacterial strains and most of them showed high antibacterial activities that were confirmed by QSAR study. Electron-withdrawing substituents are lower the HOMO energy, and increase (\(\kappa\) index) represents a positive contribution to the antibacterial activity.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vitorovic-Todorovi, M.D.; Eric-Nikoli, A.; Kolundzija, B.; Hamel, E.; Risti, S.; Jurani, I.O.; Drakuli, B.J. (E)-4-Aryl-4-oxo-2-butenoic acid amides, chalconeacrylactyl acid chimeras: Design, antiproliferative activity and inhibition of tubulin polymerization. Eur. J. Med. Chem. 2013, 62, 40–50. [CrossRef] [PubMed]

2. Dimmock, J.R.; Elias, D.W.; Beazely, M.A.; Kandepu, N.M. Bioactivites of Chalcones. Curr. Med. Chem. 1999, 6, 1125–1146. [PubMed]

3. Carlo, G.D.; Mascolo, N.; Izzo, A.A.; Capasso, F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci. 1999, 65, 337–348. [PubMed]

4. Hwang, K.; Kim, H.; Han, I.; Kim, B. Synthesis of heterocyclic chalcone derivatives and their radical scavenging ability toward 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radicals. Bull. Korean Chem. Soc. 2012, 33, 2585–2591. [CrossRef]

5. Tran, T.; Nguyen, T.; Do, T.; Huynh, T.; Tran, C.; Thai, K. Synthesis and antibacterial activity of some heterocyclic chalcone analogues alone and in combination with antibiotics. Molecules 2012, 17, 6684–6696. [CrossRef] [PubMed]

6. Saini, R.K.; Kumari, N.; Joshi, Y.C.; Joshi, P.; Shekhawat, S.S. Solvent free microwave assisted synthesis of chalcones and their antifungal activities. Asian J. Chem. 2007, 19, 4483–4496.

7. Toshihiro, S.M.; Minoru, H.; Yuji, T.; Toshiyuki, S.; Takunobu, O.; Osamu, O.; Katsumasa, K.; Hidefumi, H.; Masayasu, G.; Akira, I.; et al. Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 2009, 19, 1564–1576.

8. Hurwitz, A.; Ruhl, C.E.; Kimler, B.F.; Topp, E.M.; Mayo, M.S. Gastric function in the elderly: Effects on absorption of ketoconazole. J. Clin. Pharmacol. 2003, 43, 996–1009. [CrossRef] [PubMed]

9. Dariusz, A.P.; Andrzej, M.B.; Agniesz, E.L.; Bohdan, J.S.; Jerzy, K. Synthesis of 1-[4-[4-(adamant-1-yl)phenoxymethyl]-2-(4-bromophenyl)-1,3-dioxolan-2-yl-methyl]imidazole with expected antifungal and antibacterial activity. Acta Pol. Pharm. Drug Res. 2007, 64, 535–544.

10. Justyna, Q.; Dorota, O.; Zofia, Z.; Ewa, A.; Lucjusz, Z. Synthesis of 2,3-dihydro-7-nitro-imidazo [5,1-b]oxazole as potential tuberculostatic agents. Acta Pol. Pharm. Drug Res. 2008, 65, 543–551.

11. El-Hashash, M.; Rizk, S.; Aburzeza, M. Utility of p-acetamidobenzoyl prop-2enoic acid in the synthesis of new α-amino acids and using them as building blocks in heterocyclic synthesis. Egypt J. Chem. 2011, 54, 124–131.

12. El-Hashash, M.; Rizk, S.; Aburzeza, M. Utility of p-acetamidobenzoyl prop-2enoic acid in the synthesis of some α-amino acids and using them as building blocks in heterocyclic synthesis. Egypt J. Chem. 2011, 54, 383–391.

13. Rizk, S.A. Utility of E-1-(4-acetamidobenzoyl)-2-oxirane carboxylic acid in synthesis some fused heterocycles and spiro compounds. Ann. J. Chem. 2011, 1, 65–71. [CrossRef]
20. Rizk, S.; El-Hashash, M. 2-(3,4-Dimethylphenyl-3-(3,4-dichloro(3,4-dimethyl)) benzoyl ) propanoic acids as precursors in the synthesis of some heterocyclic compounds. *Egypt J. Chem.* 2011, 54, 567–578.

21. Rizk, S.; El-Hashash, M.; Mostafa, K. Utility of β-arylo acryl acid in heterocyclic synthesis. *Egypt J. Chem.* 2008, 51, 116–123.

22. El-Kadi, M.; El-Hashash, M.; Sayed, M. Action of Hydrazine, amine and thiourea upon 3-(4-chloro-3-methyl) benzoyl acrtyl acid. *Rev. Roum. Chim.* 1981, 26, 1161–1170.

23. El-Hashash, M.; El-Kady, M. Some reactions of 3-arylo acrtyl acid epoxides. *Rev. Roum. Chim.* 1978, 23, 1581–1589.

24. Prasad, Y.R.; Kumar, P.R.; Smiles, D.J.; Babub, P.A. QSAR studies on chalcone derivatives as antibacterial agents. *Arkivoc* 2008, xi, 266–276.

25. Azab, M.E.; Rizk, S.A.; Amr, A.E. Synthesis of some novel heterocyclic and schiff base derivatives as antimicrobial agents. *Molecules* 2015, 20, 18201–18218. [CrossRef] [PubMed]

26. Tatyan, L.P.; Fedor, G.Y.; Victoria, V.L.; Svetlana, V.S.; Oleg, V.S.; Vladimir, I.M.; Alexander, S.K. The regioselective synthesis of spirooxindolopyrrolidines and pyrrolizidines via three-component reactions of acrylamides and aroylacrylic acids with isatins and α- amino acids. *Beilstein J. Org. Chem.* 2014, 10, 117–126.

27. El-Hashash, M.A.; Rizk, S.A. Regioselective Diastereomeric michael adducts as building blocks in heterocyclic synthesis. *J. Heterocycl. Chem.* 2015, 52, 1248–1252. [CrossRef]

28. Venkataraman, L.; Park, Y.S.; Whalley, A.C.; Nuckolls, C.; Hybertsen, M.S.; Steigerwald, M.L. Electronics and chemistry: Varying single-molecule junction conductance using chemical substituents. *Nano Lett.* 2007, 7, 502–506. [CrossRef] [PubMed]

29. Parveen, Z.; Brunhofer, G.; Jabeen, I.; Erker, T.; Chiba, P.; Ecker, G.F. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein. *Bioorg. Med. Chem.* 2014, 22, 2311–2319. [CrossRef] [PubMed]

30. Takayanagri, H.; Kitano, Y.; Yano, T.; Umeki, H.; Hara, H. Bioisoster of aroyl vinylamide antitumor, and tyrosine kinase inhibition. *J. Can. Pat. Appl.* 1995, 93, 128–135.

31. Jaramillo, M.C.; Mora, C.; Vélez, L.E.; Quijano, J. Kinetic and theoretical study of the chalcones as inhibitors of beta-lactamase enzyme. *Med. Chem.* 2009, 5, 434–439. [CrossRef] [PubMed]

32. Kalagutkar, A.S.; Naguyen, H.T.; Vaz Alfin, D.N.; Dalvu, D.K.; Mcleod, D.G.; Murray, J.C. *In vitro* metabolism studies on the isoxazole ring scission in the anti-inflammatory agent leflunomide to its active α-cyanoenol metabolite a771726: Mechanistic similarities with the cytochrome p450-catalyzed dehydration of aldokines. *Drug. Metab. Dispos.* 2003, 31, 1240–1250. [CrossRef] [PubMed]

33. Mitwatashi, S.; Arikawa, Y.; Kotani, E.; Miyamoto, M.; Naruo, K.I.; Kimura, H.; Tanaka, T.; Asahi, S.; Okhawa, S. Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. *J. Med. Chem.* 2005, 48, 5966–5979. [CrossRef] [PubMed]

34. Junji, I.; Yuichiro, N.; Zhang, H.; Ryuji, U.; Kenichi, N.; Rokuro, M.; Hiroshi, T. Spirohexalines, new inhibitors of bacterial undecaprenyl pyrophosphate synthase. *J. Antibiot.* 2013, 66, 37–41.

**Sample Availability:** Samples of the compounds are available from the authors.